Colorectal cancer

Homerton University Hospital NHS Foundation Trust, London E9 6SR.
BMJ (online) (Impact Factor: 17.45). 11/2007; 335(7622):715-8. DOI: 10.1136/bmj.39321.527384.BE
Source: PubMed
14 Reads
  • Source
    • "Images can be captured in 5–10 minutes, although a further period lasting 20–30 minutes is required to reconstruct and interpret them. If the result is positive, performing a colonoscopy is mandatory, ideally on the same day or the next day in order to avoid further intestinal preparation.130–132,134,135 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer is a worldwide problem as it will affect one in three men and one in four women during their lifetime. Colorectal cancer (CRC) is the third most frequent cancer in men, after lung and prostate cancer, and is the second most frequent cancer in women after breast cancer. It is also the third cause of death in men and women separately, and is the second most frequent cause of death by cancer if both genders are considered together. CRC represents approximately 10% of deaths by cancer. Modifiable risk factors of CRC include smoking, physical inactivity, being overweight and obesity, eating processed meat, and drinking alcohol excessively. CRC screening programs are possible only in economically developed countries. However, attention should be paid in the future to geographical areas with ageing populations and a western lifestyle.19,20 Sigmoidoscopy screening done with people aged 55-64 years has been demonstrated to reduce the incidence of CRC by 33% and mortality by CRC by 43%.
    Clinical Medicine Insights: Gastroenterology 07/2014; 7:33-46. DOI:10.4137/CGast.S14039
  • Source
    • "Colorectal cancer (CRC) is a major worldwide health problem with high incidence and mortality [1-3]. In present, CRC accompanied with higher mortality is due to the disease that is frequently diagnosed in the advanced stage without reliable biomarkers. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Colorectal cancer (CRC) is known as a common malignant neoplasm worldwide. The role of EGFR/HER2 in CRC is unclear. Afatinib is an irreversible EGFR/HER2 inhibitor. There were few studies of afatinib on CRC. Here, we investigated the protein levels/expressions of HER2 in sera and tumors from CRC patients and the therapeutic effect of afatinib on HER2-overexpressed CRC in vitro and in vivo. The increased HER2 levels were detected in the collected sera and tumors of patients with CRC. The serological HER2 levels were correlated with the tumor HER2 expressions in patients. Afatinib also inhibited the HER2-positive tumor cell growth and caused apoptosis in HER2-overexpressed human colorectal cancer HCT-15 cells but not in low HER2 expressed human gastric cancer MKN45 cells. In vivo study showed that afatinib reduced tumor growth in HER2-overexpressed xenografts. Moreover, afatinib-encapsulated micelles displayed higher cytotoxic activity in HCT-15 cells and were more effective for tumor growth suppression in HCT-15-induced tumor xenografts than afatinib performance alone. Taken together, these findings suggest that higher serum HER2 levels reflect the higher HER2 contents in tumors of CRC patients, and the improved afatinib-encapsulated micelles possess high therapeutic efficacy in HER2-overexpressed CRC in vitro and in vivo.
    Oncotarget 06/2014; 5(13). DOI:10.18632/oncotarget.2050 · 6.36 Impact Factor
  • Source

    BMJ (online) 12/2007; 335(7627):953. DOI:10.1136/bmj.39388.457662.1F · 17.45 Impact Factor
Show more


14 Reads
Available from